OCP/DARS new clinical studies IDIQ 5 year contract with M ceiling

The Food and Drug Administration is planning to establish a five-year Indefinite Delivery Indefinite Quantity (IDIQ) contract to support new clinical studies under the OCP/DARS program. This contract will have a ceiling value of $50 million and is designed to facilitate various clinical research activities over the course of the agreement period. The contract falls under the NAICS code 541714, which covers research and development in biotechnology. While specific details such as the solicitation number and the exact location of performance have not been disclosed, the FDA has identified a program point of contact for acquisitions and will soon designate a contracting officer. This forecasted opportunity aims to provide a flexible mechanism for acquiring clinical study services as needed, ensuring continuous support for the FDA’s research objectives. Interested parties can reach out to the designated acquisition liaison via email for additional information.